Yasir Sepah, None;
Diana Do, Genentech (F), iCo Therapeutics (F), Regeneron (F);
David Callanan, Alcon (C), Allergan (C), Bausch and Lomb (C), Forsight Inc. (I);
Victor Gonzalez, Alcon (F), Alimera Sciences (F), Allergan (F), Ampio (F), Bausch and Lomb (F), Bayer Inc. (F), DRCR.net (F), Eyetech (F), Genentech Inc. (F), Iconic (F), Iconic Pharmaceuticals (F), Ista Pharmaceuticals (F), Janix (F), Lpath (F), Ophthotec (F), Pfizer (F), Quark (F), Regeneron (F), Thrombogenics (F), Valeant (F);
Lawrence Halperin, Covalent Medical (I);
Brian Berger, Acucela (F), Alcon labs (F), Alimera Sciences (F), Allergan (F), ALLERGAN ADVISORY PANEL (C), Ampio Pharmaceuticals (F), Comentis (F), DRCR.net (F), Genentech (F), Genera (F), Glaxo Smith Kline (F), iCo Therapeutics (F), Lpath (F), Lux Biosciences (F), MacuSight (F), Ophthotech (F), Pfizer Inc. (F), Santen Advisory Board (C), Thrombogenics (F), XOMA (F);
Mostafa Hanout, None;
Peter Hnik, iCo Therapeutics (E);
Quan Dong Nguyen, Genentech (F), iCo Therapeutics (F), Regeneron (F)